Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 multicenter study of relugolix tablets (QLG1080) in hormone-sensitive advanced prostate cancer
CTR20244923Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tissue-plasminogen activator in prostate cancer (PCa), sponsored by Qilu Pharmaceutical. Started Mar 2025; status: active.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20244923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244923.